CHIT1

Summary

CHIT1 (chitinase 1, HGNC:1936) is a protein-coding gene on chromosome 1q32.1, encoding Chitotriosidase-1 (Q13231). Degrades chitin, chitotriose and chitobiose.

Chitotriosidase is secreted by activated human macrophages and is markedly elevated in plasma of Gaucher disease patients. The expression of chitotriosidase occurs only at a late stage of differentiation of monocytes to activated macrophages in culture. Human macrophages can synthesize a functional chitotriosidase, a highly conserved enzyme with a strongly regulated expression. This enzyme may play a role in the degradation of chitin-containing pathogens. Several alternatively spliced transcript variants have been described for this gene.

Source: NCBI Gene 1118 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 251 total
• Phenotypes (HPO): 1
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_003465

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1936
Approved symbol	CHIT1
Name	chitinase 1
Location	1q32.1
Locus type	gene with protein product
Status	Approved
Aliases	CHIT, CHI3
Ensembl gene	ENSG00000133063
Ensembl biotype	protein_coding
OMIM	600031
Entrez	1118

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 12 protein_coding, 5 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000255427, ENST00000367229, ENST00000460619, ENST00000479483, ENST00000484834, ENST00000491855, ENST00000503786, ENST00000506427, ENST00000513472, ENST00000903373, ENST00000903374, ENST00000956201, ENST00000956202, ENST00000956203, ENST00000956204, ENST00000956205, ENST00000956206, ENST00000956207, ENST00000956208

RefSeq mRNA: 2 — MANE Select: NM_003465 NM_001256125, NM_003465

CCDS: CCDS1436, CCDS58057

Canonical transcript exons

ENST00000367229 — 11 exons

Exon	Start	End
ENSE00000907172	203223135	203223259
ENSE00001443883	203216079	203217133
ENSE00003468954	203225669	203225870
ENSE00003515435	203222202	203222325
ENSE00003569737	203228533	203228562
ENSE00003607590	203217739	203217865
ENSE00003612171	203223495	203223660
ENSE00003614339	203219664	203219849
ENSE00003617019	203225048	203225104
ENSE00003641539	203219216	203219329
ENSE00003850756	203229612	203229673

Expression profiles

Bgee: expression breadth ubiquitous, 168 present calls, max score 89.34.

FANTOM5 (CAGE): breadth broad, TPM avg 152.3203 / max 16195.2405, expressed in 309 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
16810	151.2393	187
16812	0.8801	137
16811	0.1909	44
16807	0.0100	6

Top tissues by expression

290 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
bone marrow	UBERON:0002371	89.34	gold quality
trabecular bone tissue	UBERON:0002483	84.85	gold quality
bone marrow cell	CL:0002092	83.41	gold quality
lymph node	UBERON:0000029	82.54	gold quality
amniotic fluid	UBERON:0000173	79.25	gold quality
spleen	UBERON:0002106	75.30	gold quality
blood	UBERON:0000178	72.52	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	72.20	gold quality
granulocyte	CL:0000094	71.89	gold quality
right lung	UBERON:0002167	69.94	gold quality
subcutaneous adipose tissue	UBERON:0002190	69.02	gold quality
upper lobe of left lung	UBERON:0008952	68.94	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	66.38	gold quality
upper lobe of lung	UBERON:0008948	66.34	gold quality
rectum	UBERON:0001052	64.84	gold quality
leukocyte	CL:0000738	64.58	gold quality
monocyte	CL:0000576	64.46	gold quality
mononuclear cell	CL:0000842	64.33	gold quality
spinal cord	UBERON:0002240	63.86	gold quality
prefrontal cortex	UBERON:0000451	63.30	gold quality
vermiform appendix	UBERON:0001154	62.91	gold quality
lung	UBERON:0002048	62.39	gold quality
endometrium epithelium	UBERON:0004811	62.12	gold quality
adipose tissue	UBERON:0001013	62.09	gold quality
connective tissue	UBERON:0002384	61.80	gold quality
Brodmann (1909) area 10	UBERON:0013541	61.34	gold quality
right frontal lobe	UBERON:0002810	61.32	gold quality
visceral pleura	UBERON:0002401	61.28	gold quality
cingulate cortex	UBERON:0003027	60.74	gold quality
omental fat pad	UBERON:0010414	60.68	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.45
E-MTAB-9801	yes	8.40

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

37 targeting CHIT1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-6715A-3P	99.83	68.05	1473
HSA-MIR-10393-5P	99.65	68.01	1368
HSA-MIR-3136-3P	99.57	66.59	781
HSA-MIR-7155-3P	99.57	66.48	794
HSA-MIR-3609	99.52	69.89	2587
HSA-MIR-548AH-5P	99.52	69.73	2626
HSA-MIR-486-3P	99.51	66.82	1901
HSA-MIR-4688	99.48	64.68	828
HSA-MIR-6743-5P	99.48	63.60	721
HSA-MIR-6513-5P	99.43	67.81	1071
HSA-MIR-1912-3P	99.32	67.40	936
HSA-MIR-422A	99.18	65.83	550
HSA-MIR-1295B-5P	99.03	67.50	810
HSA-MIR-1911-5P	98.92	67.53	325
HSA-MIR-423-5P	98.69	67.48	1522
HSA-MIR-4680-3P	98.64	68.60	2093
HSA-MIR-3184-5P	98.56	67.13	1491
HSA-MIR-5187-5P	98.54	67.94	952
HSA-MIR-1199-5P	98.44	66.51	829
HSA-MIR-6751-3P	98.44	66.35	835
HSA-MIR-378A-3P	98.43	66.10	548
HSA-MIR-378B	98.43	65.36	573
HSA-MIR-378C	98.43	66.10	548
HSA-MIR-378D	98.43	66.10	548
HSA-MIR-378E	98.43	65.99	551
HSA-MIR-378F	98.43	65.66	554
HSA-MIR-378H	98.43	66.16	545

Literature-anchored findings (GeneRIF, showing 40)

• In beta-thalassemia patients, a significant correlation exists between plasma chitotriosidase & ferritin & with mean number of transfusions per year. Normal levels in children and increased levels in only some adults may reflect macrophage iron overload. (PMID:12221666)
• hypothesis that human chitotriosidase may have anti-fungal action was studied by ascertaining the prevalence of homozygosity for the mutation of chitotriosidase among survivors of Candida sepsis (PMID:12482412)
• Increased serum chitotriosidase activity in individuals suffering from atherosclerosis is related to the severity of the atherosclerotic lesion and suggests a possible role of chitotriosidase as atherosclerotic extent marker. (PMID:12893688)
• chitotriosidase is conserved across the evolutionary scale (PMID:15218258)
• chitotriosidase and CCL18 have roles in formation of pathological lipid-laden macrophages in type B Niemann-Pick disease (PMID:15702402)
• Promoter variation in chitotriosidase is associated with the risk for serious infection in children undergoing therapy for acute myeloid leukemia (PMID:16107886)
• CHIT over-produced by Kupffer cells may contribute to the progression of hepatic fibrosis. (PMID:16848812)
• This review is looks at the key areas of investigations addressed to further illuminate whether ChT activation might have different functional meanings in various diseases. (PMID:17075695)
• Formation of peritrophic membrane(PM) was complete at 16 h in the posterior midgut from Anopheles fed with healthy donor bloods; by contrast, PM in mosquitoes fed with malaria and Gaucher patient bloods appeared clearly damaged at 20 and 24 h. (PMID:17136386)
• serum chitotriosidase activity predicts the risk of new cardiovascular events in the following 4 years. (PMID:17290100)
• Plasma chitotriosidase activity in Gaucher disease,GM1-gangliosidosis and Krabbe disease patients was, respectively, around 600-fold, 15-fold and 12-fold greater than in normal individuals. (PMID:17291472)
• there are statistical differences between levels of chitotriosidase in elderly and young subjects (PMID:17460177)
• Null and hypomorphic novel chitotriosidase mutations in type 1 Gaucher disease. (PMID:17464953)
• examination of allele frequency of subjects of European, Asian & African ancestry compared to enzyme activity; investigated possibility that chitotriosidase deficiency was associated with tuberculosis or atopies (PMID:17693102)
• the CHIT1 genotype does not play a crucial role in protection against hookworm infection (PMID:17765019)
• Results suggest that 24 bp duplication of CHIT1 gene is not correlated with CAD in Corsican population. (PMID:17916351)
• NOD2 activation, but not toll-like receptor stimulation, induces chitinase expression in macrophages (PMID:17976376)
• activity in maternal and cord serum significantly higher in pre-eclamptic pregnancies (PMID:18054022)
• Human chitotriosidase is expressed in the eye and lacrimal gland and has an antimicrobial spectrum different from lysozyme. (PMID:18068392)
• significantly different chitotriosidase concentrations were found in bronchoalveolar lavage (BAL) of sarcoidosis patients than controls especially in patients with progressing disease (PMID:18069420)
• Examination of levels and chitotriosidase activity both in benign prostatic hyperplasia and primary prostate cancer. (PMID:18190830)
• in patients with Juvenile idiopathic arthritis: chitotriosidase level in synovial fluid was up to approximately 1,000 nmol/(h ml) at disease onset before therapy. The level in the sera was below 600 nmol/(h ml (PMID:18324378)
• The higher chitotriosidase (ChT) activity in milk of mothers of premature infants than those of full-term infants suggests the presence of activated macrophages as the main source of ChT. (PMID:18355455)
• Chitotriosidase and sIL-2R are two markers of sarcoidosis of different origin, the values of which show a correlation in these patients (PMID:18609101)
• The high levels of chitinase activity in habitual smokers result from upregulation of CHIT1 gene expression, especially in macrophages. (PMID:18845328)
• Results showed the presence of CHIT1 and AMCase mRNA in gastric mucosa and the correlation with the presence of H. pylori was significant only for CHIT1 but not for AMCase expression. (PMID:19242357)
• The results confirm that chitotriosidase activity is markedly increased in some cases of sarcoidosis. (PMID:19347743)
• PRL up-regulated CHIT-1 expression via PTK, PI3-K, MAPK, and signaling transduction components. (PMID:19415692)
• asthma susceptibility genes; review of genetic and fuctional studies (PMID:19644363)
• impact of a known polymorphism, G102S, on the catalytic properties of CHIT1. The G102S allele was found to be common in type I Gaucher disease patients in the Netherlands ( approximately 24% of alleles). (PMID:19725875)
• Determination of plasma chitotriosidase and CCL18 may be useful to monitor changes in granulomatous macrophages during the course of sarcoidosis (PMID:19808030)
• These data indicate that the heterozygosis for a 24-bp duplication in the CHIT-1 gene could have a protective effect in human longevity. (PMID:19881466)
• The chitotriosidase index is elevated in multiple sclerosis. The chitotriosidase index is related to CSF markers of inflammation or immune activation (PMID:19925532)
• Serum chitotriosidase enzyme activity has limited utility as a biomarker in Wegener’s granulomatosis patients. (PMID:19958755)
• CHIT1 deficiency was evaluated in 122 Brazilian healthy volunteers for enzyme activity & genotype. The frequency of the 24 bp mutation in our sample (30%) is higher than in African & European populations, but lower than most Asian populations. (PMID:20178893)
• Our study found no associations between single nucleotide polymorphisms in the genes CHIT1, CHIA, and CHI3L1 and asthma, changes in lung physiology, or allergy-related phenotypes in subjects with mild-to-moderate asthma (PMID:20226308)
• investigated the possible associations between polymorphisms in CHIT1, MBL2 and sepsis in adult patients treated with high-dose chemotherapy for AML (PMID:20331735)
• The levels of expression of AMCase and chitotriosidase mRNAs and proteins were increased in allergic turbinate mucosa compared with normal turbinate mucosa. (PMID:20422678)
• Environmental exposure to fungi modifies the effect of CHIT1 SNPs on severe asthma exacerbations (PMID:20538957)
• Reduction in imiglucerase dosage causes immediate rise of chitotriosidase activity in patients with Gaucher disease (PMID:20580583)

Cross-species orthologs

44 orthologs

Organism	Symbol	Gene ID
danio_rerio	chia.1	ENSDARG00000100635
mus_musculus	Chit1	ENSMUSG00000026450
rattus_norvegicus	Chit1	ENSRNOG00000028072
drosophila_melanogaster	Idgf6	FBGN0013763
drosophila_melanogaster	Idgf3	FBGN0020414
drosophila_melanogaster	Idgf2	FBGN0020415
drosophila_melanogaster	Idgf1	FBGN0020416
drosophila_melanogaster	Cht4	FBGN0022700
drosophila_melanogaster	Idgf4	FBGN0026415
drosophila_melanogaster	Cht8	FBGN0034580
drosophila_melanogaster	Cht9	FBGN0034582
drosophila_melanogaster	Cht7	FBGN0035398
drosophila_melanogaster	Cht12	FBGN0050293
drosophila_melanogaster	Cda4	FBGN0052499
drosophila_melanogaster	Idgf5	FBGN0064237
drosophila_melanogaster	Cht10	FBGN0250907
caenorhabditis_elegans		WBGENE00000503
caenorhabditis_elegans		WBGENE00007465
caenorhabditis_elegans		WBGENE00007466
caenorhabditis_elegans		WBGENE00007467
caenorhabditis_elegans		WBGENE00007469
caenorhabditis_elegans		WBGENE00007470
caenorhabditis_elegans		WBGENE00007471
caenorhabditis_elegans		WBGENE00007472
caenorhabditis_elegans		WBGENE00007473
caenorhabditis_elegans		WBGENE00010799
caenorhabditis_elegans		WBGENE00010945
caenorhabditis_elegans		WBGENE00011157
caenorhabditis_elegans		WBGENE00011158
caenorhabditis_elegans		WBGENE00011159
caenorhabditis_elegans		WBGENE00011161
caenorhabditis_elegans		WBGENE00011162
caenorhabditis_elegans		WBGENE00011164
caenorhabditis_elegans		WBGENE00011166
caenorhabditis_elegans		WBGENE00011167
caenorhabditis_elegans		WBGENE00011170
caenorhabditis_elegans		WBGENE00011846
caenorhabditis_elegans		WBGENE00014162
caenorhabditis_elegans		WBGENE00016665
caenorhabditis_elegans		WBGENE00017233
caenorhabditis_elegans		WBGENE00020141
caenorhabditis_elegans		WBGENE00020407
caenorhabditis_elegans		WBGENE00044546
caenorhabditis_elegans		WBGENE00044807

Paralogs (6): CHI3L2 (ENSG00000064886), OVGP1 (ENSG00000085465), CTBS (ENSG00000117151), CHI3L1 (ENSG00000133048), CHIA (ENSG00000134216), CHID1 (ENSG00000177830)

Protein

Protein identifiers

Chitotriosidase-1 — Q13231 (reviewed: Q13231)

Alternative names: Chitinase-1

All UniProt accessions (2): D6REY1, Q13231

UniProt curated annotations — full annotation on UniProt →

Function. Degrades chitin, chitotriose and chitobiose. May participate in the defense against nematodes and other pathogens. Isoform 3 has no enzymatic activity.

Subunit / interactions. Monomer.

Subcellular location. Secreted. Lysosome.

Tissue specificity. Detected in spleen. Secreted by cultured macrophages.

Polymorphism. A 24 bp duplication in exon 10 leads to the activation of an alternative splice site and the production of an inactive protein resulting in chitotriosidase deficiency [MIM:614122]. About 6% of the population are deficient for CHIT1 activity, while 35% are carriers and show reduced enzyme levels. People with CHIT1 deficiency appear perfectly healthy.

Miscellaneous. Very high plasma levels of CHIT1 are found in patients with Gaucher disease type 1 (GD I). Can be used as diagnostic aid and to evaluate the success of treatment that brings levels back to normal. Duplication of 24 bp in exon 10 leads to the use of a cryptic splice site. The normal splice site is still present but not used.

Similarity. Belongs to the glycosyl hydrolase 18 family. Chitinase class II subfamily.

Isoforms (4)

UniProt ID	Names	Canonical?
Q13231-1	1	yes
Q13231-2	2
Q13231-3	3
Q13231-4	4

RefSeq proteins (2): NP_001243054, NP_003456* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001223	Glyco_hydro18_cat	Domain
IPR001579	Glyco_hydro_18_chit_AS	Active_site
IPR002557	Chitin-bd_dom	Domain
IPR011583	Chitinase_II/V-like_cat	Domain
IPR017853	GH_hydrolase_sf	Homologous_superfamily
IPR029070	Chitinase_insertion_sf	Homologous_superfamily
IPR036508	Chitin-bd_dom_sf	Homologous_superfamily
IPR050314	Glycosyl_Hydrlase_18	Family

Pfam: PF00704, PF01607

UniProt features (68 total): strand 22, helix 16, turn 6, binding site 5, sequence variant 5, splice variant 4, disulfide bond 3, domain 2, signal peptide 1, chain 1, glycosylation site 1, region of interest 1, active site 1

Structure

Experimental structures (PDB)

23 structures.

PDB	Method	Resolution (Å)
4WKA	X-RAY DIFFRACTION	0.95
4WJX	X-RAY DIFFRACTION	1
4WKH	X-RAY DIFFRACTION	1.05
4WKF	X-RAY DIFFRACTION	1.1
4WK9	X-RAY DIFFRACTION	1.1
5NRA	X-RAY DIFFRACTION	1.27
5NR8	X-RAY DIFFRACTION	1.35
5NRF	X-RAY DIFFRACTION	1.45
6ZE8	X-RAY DIFFRACTION	1.5
6JK6	X-RAY DIFFRACTION	1.57
1WB0	X-RAY DIFFRACTION	1.65
1WAW	X-RAY DIFFRACTION	1.75
6JJR	X-RAY DIFFRACTION	1.83
1HKK	X-RAY DIFFRACTION	1.85
5HBF	X-RAY DIFFRACTION	1.95
1LG2	X-RAY DIFFRACTION	2.1
1LQ0	X-RAY DIFFRACTION	2.2
1GUV	X-RAY DIFFRACTION	2.35
1HKI	X-RAY DIFFRACTION	2.55
1HKM	X-RAY DIFFRACTION	2.55
1HKJ	X-RAY DIFFRACTION	2.6
1LG1	X-RAY DIFFRACTION	2.78
6SO0	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q13231-F1	91.72	0.86

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 140 (proton donor)

Ligand- & substrate-binding residues (5): 358; 70–71; 97–100; 141; 210–213

Disulfide bonds (3): 26–51, 307–370, 450–463

Glycosylation sites (1): 100

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-189085	Digestion of dietary carbohydrate
R-HSA-6798695	Neutrophil degranulation

MSigDB gene sets: 107 (showing top): MODULE_172, GOBP_DIGESTION, REACTOME_INNATE_IMMUNE_SYSTEM, GOCC_SECRETORY_GRANULE, REACTOME_DIGESTION_OF_DIETARY_CARBOHYDRATE, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_CATABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_POLYSACCHARIDE_CATABOLIC_PROCESS, MODULE_75, WATANABE_RECTAL_CANCER_RADIOTHERAPY_RESPONSIVE_UP, GOBP_AMINOGLYCAN_METABOLIC_PROCESS, GOBP_CARBOHYDRATE_METABOLIC_PROCESS, MODULE_410, GOBP_AMINO_SUGAR_CATABOLIC_PROCESS

GO Biological Process (6): polysaccharide catabolic process (GO:0000272), chitin catabolic process (GO:0006032), immune response (GO:0006955), response to bacterium (GO:0009617), polysaccharide digestion (GO:0044245), carbohydrate metabolic process (GO:0005975)

GO Molecular Function (7): hydrolase activity, hydrolyzing O-glycosyl compounds (GO:0004553), chitinase activity (GO:0004568), chitin binding (GO:0008061), endochitinase activity (GO:0008843), protein binding (GO:0005515), hydrolase activity (GO:0016787), hydrolase activity, acting on glycosyl bonds (GO:0016798)

GO Cellular Component (5): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), lysosome (GO:0005764), specific granule lumen (GO:0035580), tertiary granule lumen (GO:1904724)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Digestion	1
Innate Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
polysaccharide metabolic process	1
macromolecule catabolic process	1
carbohydrate catabolic process	1
aminoglycan catabolic process	1
chitin metabolic process	1
glucosamine-containing compound catabolic process	1
immune system process	1
response to stimulus	1
response to other organism	1
digestion	1
primary metabolic process	1
hydrolase activity, acting on glycosyl bonds	1
hydrolase activity, hydrolyzing O-glycosyl compounds	1
carbohydrate derivative binding	1
chitinase activity	1
binding	1
catalytic activity	1
hydrolase activity	1
cellular anatomical structure	1
lytic vacuole	1
secretory granule lumen	1
specific granule	1
intracellular organelle lumen	1
tertiary granule	1

Protein interactions and networks

STRING

1562 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CHIT1	GBA1	P04062	924
CHIT1	UGCG	Q16739	923
CHIT1	PSAP	P07292	791
CHIT1	LYZ	P00695	790
CHIT1	NPC1	O15118	720
CHIT1	ARG1	P05089	718
CHIT1	IL13	P35225	705
CHIT1	CHID1	Q9BWS9	683
CHIT1	SLC5A7	Q9GZV3	665
CHIT1	CCL18	P55774	664
CHIT1	NPC2	P61916	650
CHIT1	RETNLB	Q9BQ08	591
CHIT1	MRC1	P22897	589
CHIT1	IL4	P05112	585
CHIT1	STAB1	Q9NY15	576

IntAct

8 interactions, top by confidence:

A	B	Type	Score
ALDH3B1	UBA6	psi-mi:“MI:0914”(association)	0.530
CHIT1	VHL	psi-mi:“MI:0915”(physical association)	0.500
CHIT1	H1-2	psi-mi:“MI:0915”(physical association)	0.400
CHIT1	VHL	psi-mi:“MI:0914”(association)	0.350
CHIT1	SMAD7	psi-mi:“MI:0914”(association)	0.350
KLK10	IGLL5	psi-mi:“MI:0914”(association)	0.350

BioGRID (14): CHIT1 (Affinity Capture-MS), VHL (Affinity Capture-MS), RMDN1 (Affinity Capture-MS), RPL11 (Affinity Capture-MS), CHIT1 (Affinity Capture-MS), CHIT1 (Proximity Label-MS), VHL (Affinity Capture-MS), CTU1 (Affinity Capture-MS), CHIT1 (Affinity Capture-MS), SMAD7 (Affinity Capture-MS), BLK (Affinity Capture-MS), CTU2 (Affinity Capture-MS), RMDN1 (Affinity Capture-MS), CHIT1 (Affinity Capture-MS)

ESM2 similar proteins: A0A0W0FPC8, A0A2U7QU15, A1CRV0, A1CX14, A1D4Q5, A1DCV5, A1DME8, A2RAR6, A5ABF5, A6N6J0, B0XN12, B0YB65, B6GX22, B7SIW2, B8NKA3, C5P230, D4B4X4, E9ERT9, E9QRF2, G4NI45, G5EAZ3, O14456, O93983, P0C1B3, P0C1B4, P0CB51, P29717, P30292, P32470, P41684, P48827, Q02905, Q02906, Q12713, Q12725, Q13231, Q1E3R8, Q2PGV8, Q2U790, Q4WGT3

Diamond homologs: A0A072UR65, A0A072VEP0, A0A1B1J8Z2, A6N6J0, E9ERT9, O35744, O81862, P29030, P36222, P36362, P36718, P48827, Q12889, Q13231, Q15782, Q28042, Q28542, Q28990, Q29411, Q5RBP6, Q62010, Q6RY07, Q91XA9, Q91Z98, Q95M17, Q9BZP6, Q9W092, Q9W5U2, U5N4E3, O14456, P20533, P30922, P36909, Q60557, Q6TMG6, Q8SPQ0, A0A0A2JVV3, C5P230, E9QRF2, G5EAZ3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

251 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	87
Likely benign	54
Benign	41

Top pathogenic / likely-pathogenic (0)

SpliceAI

1984 predictions. Top by Δscore:

Variant	Effect	Δscore
1:203217733:A:AC	donor_gain	1.0000
1:203217734:C:CC	donor_gain	1.0000
1:203217735:TTA:T	donor_loss	1.0000
1:203217736:TA:T	donor_loss	1.0000
1:203217737:A:AC	donor_gain	1.0000
1:203217738:C:CC	donor_gain	1.0000
1:203217738:C:CG	donor_loss	1.0000
1:203217738:CT:C	donor_gain	1.0000
1:203217741:AGTT:A	donor_gain	1.0000
1:203219326:AGACC:A	acceptor_loss	1.0000
1:203219329:CCT:C	acceptor_loss	1.0000
1:203219330:C:CG	acceptor_loss	1.0000
1:203219331:T:A	acceptor_loss	1.0000
1:203219662:A:AC	donor_gain	1.0000
1:203219663:C:CC	donor_gain	1.0000
1:203219665:T:TA	donor_gain	1.0000
1:203219682:C:A	donor_gain	1.0000
1:203219685:T:TA	donor_gain	1.0000
1:203219689:T:A	donor_gain	1.0000
1:203222199:TA:T	donor_loss	1.0000
1:203222200:A:AC	donor_gain	1.0000
1:203222200:A:AT	donor_loss	1.0000
1:203222201:C:CC	donor_gain	1.0000
1:203222201:CCA:C	donor_gain	1.0000
1:203222201:CCACG:C	donor_gain	1.0000
1:203222321:GGTTC:G	acceptor_gain	1.0000
1:203222322:GTTC:G	acceptor_gain	1.0000
1:203222323:TTC:T	acceptor_gain	1.0000
1:203222324:TC:T	acceptor_gain	1.0000
1:203222324:TCC:T	acceptor_loss	1.0000

AlphaMissense

3059 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:203219228:G:C	S339R	0.985
1:203219228:G:T	S339R	0.985
1:203219230:T:G	S339R	0.985
1:203225850:A:G	C26R	0.978
1:203225774:C:G	C51S	0.976
1:203225775:A:T	C51S	0.976
1:203217808:C:G	D363H	0.971
1:203225848:G:C	C26W	0.971
1:203225773:G:C	C51W	0.969
1:203225849:C:G	C26S	0.968
1:203225850:A:T	C26S	0.968
1:203225849:C:T	C26Y	0.967
1:203225084:A:G	L93P	0.966
1:203225775:A:G	C51R	0.965
1:203225774:C:T	C51Y	0.961
1:203216922:G:C	F456L	0.959
1:203216922:G:T	F456L	0.959
1:203216924:A:G	F456L	0.959
1:203225765:A:G	L54P	0.959
1:203217031:C:G	C420S	0.954
1:203217032:A:T	C420S	0.954
1:203222253:G:C	S226R	0.954
1:203222253:G:T	S226R	0.954
1:203222255:T:G	S226R	0.954
1:203219216:C:A	K343N	0.953
1:203219216:C:G	K343N	0.953
1:203223579:A:C	F132L	0.952
1:203223579:A:T	F132L	0.952
1:203223581:A:G	F132L	0.952
1:203219766:G:C	F271L	0.949

dbSNP variants (sampled 300 via entrez): RS1000202023 (1:203225164 G>A), RS1000251910 (1:203218967 A>G), RS1000335574 (1:203230344 C>T), RS1000475643 (1:203225667 A>G), RS1000584789 (1:203220265 T>C,G), RS1000586382 (1:203220477 A>T), RS1000615890 (1:203231022 C>G), RS1000779135 (1:203230987 G>A), RS1000888672 (1:203225465 C>A,T), RS1001032614 (1:203220674 C>T), RS1001283217 (1:203228868 G>A), RS1001335585 (1:203229088 C>T), RS1001613548 (1:203223828 A>G), RS1001685921 (1:203218025 T>A,C,G), RS1002019593 (1:203219513 A>G)

Disease associations

OMIM: gene MIM:600031 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST002595_27	Clozapine-induced agranulocytosis	9.000000e-06
GCST009798_35	Asthma	8.000000e-12

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3080 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 206 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL4788866	5-(4-((2S,5S)-5-(4-CHLOROBENZYL)-2-METHYLMORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-TRIAZOL-3-AMINE	2	206

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Chitinases

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
GLPG4716	Inhibition	7.64	pIC50

Binding affinities (BindingDB)

51 measured of 93 human assays (97 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
(6R)-1′-(5-amino-4H-1,2,4-triazol-3-yl)-6-(4-chlorobenzyl)-[1,4′-bipiperidine]-3-carboxylic acid	IC50	550 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
5-((2S,4S)-2-(4-chlorobenzyl)-4-methoxy-[1,4′-bipiperidin]-1′-yl)-4H-1,2,4-triazol-3-amine	IC50	550 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
5-(4-((2S,3S)-2-(4-chlorobenzyl)-3-methoxyazetidin-1-yl)piperidin-1-yl)-4H-1,2,4-triazol-3-amine	IC50	550 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
(S)-5-(4-(2-(4-chlorobenzyl)piperazin-1-yl)piperidin-1-yl)-4H-1,2,4-triazol-3-amine	IC50	550 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
(S)-5-(4-(2-(4-chlorobenzyl)-4-methylpiperazin-1-yl)piperidin-1-yl)-4H-1,2,4-triazol-3-amine	IC50	550 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
(S)-5-(4-(2-(4-chlorobenzyl)-4-isobutylpiperazin-1-yl)piperidin-1-yl)-4H-1,2,4-triazol-3-amine	IC50	550 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
((2R,5S)-4-(1-(5-amino-4H-1,2,4-triazol-3-yl)piperidin-4-yl)-5-(4-chlorobenzyl)-1-methylpiperazin-2-yl)methanol	IC50	550 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
methyl 2-[(2S,5S)-4-[1-(5-amino-1H-1,2,4-triazol-3-yl)piperidin-4-yl]-5-[(4-chlorophenyl)methyl]-2-methylpiperazin-1-yl]acetate	IC50	550 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
(S)-4-(1-(5-amino-4H-1,2,4-triazol-3-yl)piperidin-4-yl)-3-(4-chlorobenzyl)thiomorpholine 1,1-dioxide	IC50	550 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
5-(4-((2R,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-4H-1,2,4-triazol-3-amine	IC50	550 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
(5S)-1-(1-(5-amino-4H-1,2,4-triazol-3-yl)piperidin-4-yl)-5-(4-chlorobenzyl)-3-methylpyrrolidin-3-ol	IC50	550 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
3-((3S,4S)-4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)-3-methoxypiperidin-1-yl)-1H-1,2,4-triazol-5-amine	IC50	550 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
(S)-5-(4-(3-(4-chlorobenzyl)-6-methylene-1,4-oxazepan-4-yl)piperidin-1-yl)-4H-1,2,4-triazol-3-amine	IC50	550 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
(S)-5-(4-(3-(4-chlorobenzyl)-1-methyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-4(5H)-yl)piperidin-1-yl)-4H-1,2,4-triazol-3-amine	IC50	550 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
(S)-5-(4-(7-chloro-3-(4-chlorobenzyl)-1-methyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-4(5H)-yl)piperidin-1-yl)-4H-1,2,4-triazol-3-amine	IC50	550 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
(S)-5-(4-(3-(4-chlorobenzyl)-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)piperidin-1-yl)-4H-1,2,4-triazol-3-amine	IC50	550 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
(S)-5-(4-(3-(4-chlorobenzyl)-7-fluoro-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)piperidin-1-yl)-4H-1,2,4-triazol-3-amine	IC50	550 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
3-[4-[2-[(4-chlorophenyl)methyl]piperazin-1-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine	IC50	550 nM	US-9944624: Substituted amino triazoles useful as human chitinase inhibitors
3-[4-[2-[(4-chlorophenyl)methyl]-4-methylpiperazin-1-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine	IC50	550 nM	US-9944624: Substituted amino triazoles useful as human chitinase inhibitors
3-[4-[2-[(4-chlorophenyl)methyl]-4-(2-methylpropyl)piperazin-1-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine	IC50	550 nM	US-9944624: Substituted amino triazoles useful as human chitinase inhibitors
[(2R)-4-[1-(5-amino-1H-1,2,4-triazol-3-yl)piperidin-4-yl]-5-[(4-chlorophenyl)methyl]-1-methylpiperazin-2-yl]methanol	IC50	550 nM	US-9944624: Substituted amino triazoles useful as human chitinase inhibitors
3-[4-[3-[(4-chlorophenyl)methyl]-1,1-dioxo-1,4-thiazinan-4-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine	IC50	550 nM	US-9944624: Substituted amino triazoles useful as human chitinase inhibitors
3-[4-[(2R)-5-[(4-chlorophenyl)methyl]-2-methylmorpholin-4-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine	IC50	550 nM	US-9944624: Substituted amino triazoles useful as human chitinase inhibitors
3-[(3S)-4-[(2S)-5-[(4-chlorophenyl)methyl]-2-methylmorpholin-4-yl]-3-methoxypiperidin-1-yl]-1H-1,2,4-triazol-5-amine	IC50	550 nM	US-9944624: Substituted amino triazoles useful as human chitinase inhibitors
(2S,5S)-4-(1-(5-amino-4H-1,2,4-triazol-3-yl)piperidin-4-yl)-5-(4-chlorobenzyl)morpholine-2-carboxamide	IC50	5500 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
(6R)-1′-(5-amino-4H-1,2,4-triazol-3-yl)-6-(4-chlorobenzyl)-3-methyl-[1,4′-bipiperidine]-3-carboxylic acid	IC50	5500 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
5-((2S,4R)-2-(4-chlorobenzyl)-4-methoxy-[1,4′-bipiperidin]-1′-yl)-4H-1,2,4-triazol-3-amine	IC50	5500 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
(S)-4-(1-(5-amino-4H-1,2,4-triazol-3-yl)piperidin-4-yl)-5-(4-chlorobenzyl)piperazin-2-one	IC50	5500 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
(S)-5-(4-(2-(4-chlorobenzyl)-4-(methylsulfonyl)piperazin-1-yl)piperidin-1-yl)-4H-1,2,4-triazol-3-amine	IC50	5500 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
(S)-5-(4-(2-(4-chlorobenzyl)-4-tosylpiperazin-1-yl)piperidin-1-yl)-4H-1,2,4-triazol-3-amine	IC50	5500 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
5-(4-((2S,5S)-2-(4-chlorobenzyl)-5-methyl-4-(methylsulfonyl)piperazin-1-yl)piperidin-1-yl)-4H-1,2,4-triazol-3-amine	IC50	5500 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
(S)-4-(1-(5-amino-4H-1,2,4-triazol-3-yl)piperidin-4-yl)-3-(4-chlorobenzyl)piperazin-2-one	IC50	5500 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
5-(4-((3S,6S)-3-(4-chlorobenzyl)-2,2,6-trimethylmorpholino)piperidin-1-yl)-4H-1,2,4-triazol-3-amine	IC50	5500 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
(S)-5-(4-(7-chloro-3-(4-chlorobenzyl)-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)piperidin-1-yl)-4H-1,2,4-triazol-3-amine	IC50	5500 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
(S)-5-(4-(3-(4-chlorobenzyl)-2,3-dihydropyrido[4,3-f][1,4]oxazepin-4(5H)-yl)piperidin-1-yl)-4H-1,2,4-triazol-3-amine	IC50	5500 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
3-[4-[2-[(4-chlorophenyl)methyl]-4-methylsulfonylpiperazin-1-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine	IC50	5500 nM	US-9944624: Substituted amino triazoles useful as human chitinase inhibitors
3-[4-[2-[(4-chlorophenyl)methyl]-4-(4-methylphenyl)sulfonylpiperazin-1-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine	IC50	5500 nM	US-9944624: Substituted amino triazoles useful as human chitinase inhibitors
3-[4-[(5S)-2-[(4-chlorophenyl)methyl]-5-methyl-4-methylsulfonylpiperazin-1-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine	IC50	5500 nM	US-9944624: Substituted amino triazoles useful as human chitinase inhibitors
methyl (2S)-4-[1-(5-amino-1H-1,2,4-triazol-3-yl)piperidin-4-yl]-5-[(4-chlorophenyl)methyl]-2-methylpiperazine-1-carboxylate	IC50	5500 nM	US-9944624: Substituted amino triazoles useful as human chitinase inhibitors
4-[1-(5-amino-1H-1,2,4-triazol-3-yl)piperidin-4-yl]-3-[(4-chlorophenyl)methyl]piperazin-2-one	IC50	5500 nM	US-9944624: Substituted amino triazoles useful as human chitinase inhibitors
3-[4-[(6S)-3-[(4-chlorophenyl)methyl]-2,2,6-trimethylmorpholin-4-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine	IC50	5500 nM	US-9944624: Substituted amino triazoles useful as human chitinase inhibitors
(1′-(5-amino-4H-1,2,4-triazol-3-yl)-[1,4′-bipiperidin]-2-yl)(4-chlorophenyl)methanol	IC50	55000 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
5-(4-((2S,3R)-2-(4-chlorobenzyl)-3-fluoroazetidin-1-yl)piperidin-1-yl)-4H-1,2,4-triazol-3-amine	IC50	55000 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
5-(4-((2S,5S)-2,5-bis(4-chlorobenzyl)-4-(methyl sulfonyl)piperazin-1-yl)piperidin-1-yl)-4H-1,2,4-triazol-3-amine	IC50	55000 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
1-((2S,5S)-4-(1-(5-amino-4H-1,2,4-triazol-3-yl)piperidin-4-yl)-5-(4-chlorobenzyl)-2-methylpiperazin-1-yl)ethanone	IC50	55000 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
methyl (2S,5S)-4-[1-(5-amino-1H-1,2,4-triazol-3-yl)piperidin-4-yl]-5-[(4-chlorophenyl)methyl]-2-methylpiperazine-1-carboxylate	IC50	55000 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
(S)-5-(4-(3-(4-chlorobenzyl)-2,2-dimethylmorpholino)piperidin-1-yl)-4H-1,2,4-triazol-3-amine	IC50	55000 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
(S)-5-(4-(7,9-dichloro-3-(4-chlorobenzyl)-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)piperidin-1-yl)-4H-1,2,4-triazol-3-amine	IC50	55000 nM	US-10208020: Substituted amino triazoles useful as human chitinase inhibitors
3-[4-[(5S)-2,5-bis[(4-chlorophenyl)methyl]-4-methylsulfonylpiperazin-1-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine	IC50	55000 nM	US-9944624: Substituted amino triazoles useful as human chitinase inhibitors
1-[(2S)-4-[1-(5-amino-1H-1,2,4-triazol-3-yl)piperidin-4-yl]-5-[(4-chlorophenyl)methyl]-2-methylpiperazin-1-yl]ethanone	IC50	55000 nM	US-9944624: Substituted amino triazoles useful as human chitinase inhibitors

ChEMBL bioactivities

225 potent at pChembl≥5 of 276 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.85	Ki	1.4	nM	CHEMBL1738785
7.85	IC50	14	nM	CHEMBL4776610
7.80	IC50	16	nM	CHEMBL4756869
7.76	Ki	17.3	nM	5-(4-((2S,5S)-5-(4-CHLOROBENZYL)-2-METHYLMORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-TRIAZOL-3-AMINE
7.75	IC50	18	nM	CHEMBL4794014
7.68	IC50	21	nM	CHEMBL4464754
7.66	IC50	22	nM	CHEMBL4789376
7.66	IC50	22	nM	CHEMBL4755139
7.64	IC50	23	nM	5-(4-((2S,5S)-5-(4-CHLOROBENZYL)-2-METHYLMORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-TRIAZOL-3-AMINE
7.64	IC50	23	nM	CHEMBL4764430
7.57	IC50	27	nM	CHEMBL4541831
7.50	IC50	32	nM	CHEMBL4749391
7.44	IC50	36	nM	CHEMBL4084573
7.39	IC50	41	nM	CHEMBL4580568
7.36	IC50	44	nM	CHEMBL4470253
7.36	IC50	44	nM	CHEMBL4520755
7.33	IC50	47	nM	CHEMBL4537828
7.32	IC50	48	nM	CHEMBL4461925
7.31	Ki	49	nM	CHEMBL4549449
7.31	IC50	49	nM	CHEMBL4637417
7.31	IC50	49	nM	CHEMBL5570010
7.23	IC50	59	nM	CHEMBL4588384
7.10	IC50	79	nM	CHEMBL4634943
7.09	IC50	82	nM	CHEMBL4442663
7.08	IC50	84	nM	CHEMBL4521547
7.06	IC50	87	nM	CHEMBL4547227
7.05	IC50	90	nM	CHEMBL4646309
6.98	IC50	105	nM	CHEMBL4098997
6.98	IC50	104	nM	CHEMBL4077644
6.91	IC50	123	nM	CHEMBL4068944
6.91	IC50	123	nM	CHEMBL4082060
6.91	IC50	122	nM	CHEMBL4077482
6.89	IC50	130	nM	CHEMBL5289869
6.84	IC50	145	nM	CHEMBL4464943
6.83	IC50	149	nM	CHEMBL4077644
6.79	IC50	163	nM	CHEMBL4077482
6.76	IC50	175	nM	CHEMBL4086986
6.75	IC50	180	nM	CHEMBL4440077
6.75	IC50	176	nM	CHEMBL4649081
6.72	IC50	190	nM	CHEMBL5290116
6.70	IC50	200	nM	CHEMBL4632547
6.64	IC50	229	nM	CHEMBL4076989
6.63	IC50	232	nM	CHEMBL4076989
6.56	IC50	277	nM	CHEMBL4646247
6.56	IC50	275	nM	CHEMBL4635305
6.51	Ki	312	nM	CHEMBL4076989
6.51	IC50	310	nM	CHEMBL4642053
6.48	IC50	330	nM	CHEMBL4460797
6.47	IC50	340	nM	CHEMBL5570939
6.46	IC50	350	nM	CHEMBL4644319

PubChem BioAssay actives

128 with measured affinity, of 232 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
3,7-dimethyl-1-[3-(3-methyl-2,6-dioxo-7H-purin-1-yl)propyl]purine-2,6-dione	1952961: Inhibition of human CHIT1 using 4-methylumbelliferyl-beta-D-N,N’,N’’-triacetylchitotriose as substrate assessed as substrate hydrolysis by measuring inhibition constant preincubated with compound for 20 mins and measured immediately after substrate addition by fluorescence based assay relative to control	ki	0.0014	uM
4-[(1S,4R,10S,13S,16S,18R)-10-[3-[[acetamido(amino)methylidene]amino]propyl]-18-hydroxy-16-(1H-imidazol-5-ylmethyl)-3,9,12,15,20-pentaoxo-2,8,11,14,17-pentazatricyclo[15.2.1.04,8]icosan-13-yl]butanoic acid	1796549: Enzyme Inhibition Assay from Article 10.1016/j.chembiol.2004.10.013: “Specificity and affinity of natural product cyclopentapeptide inhibitors against A. fumigatus, human, and bacterial chitinases.”	ic50	0.0130	uM
3-[4-[(2S,5S)-5-[(4-chlorophenyl)methyl]-2-ethylmorpholin-4-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine	1699192: Inhibition of full-length C-terminal his-tagged human recombinant CHIT1 catalytic domain (1 to 386 residues) expressed in HEK293F cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N"-triacetylchitotrioside as substrate after 60 mins by fluorometric assay	ic50	0.0140	uM
3-[4-[(2S,5S)-5-[(4-chlorophenyl)methyl]-2-(2-methylpropyl)morpholin-4-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine	1699192: Inhibition of full-length C-terminal his-tagged human recombinant CHIT1 catalytic domain (1 to 386 residues) expressed in HEK293F cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N"-triacetylchitotrioside as substrate after 60 mins by fluorometric assay	ic50	0.0160	uM
3-[4-[(2S,5S)-5-[(4-chlorophenyl)methyl]-2-methylmorpholin-4-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine	1699192: Inhibition of full-length C-terminal his-tagged human recombinant CHIT1 catalytic domain (1 to 386 residues) expressed in HEK293F cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N"-triacetylchitotrioside as substrate after 60 mins by fluorometric assay	ki	0.0173	uM
3-[4-[(2S,5S)-5-[(4-chlorophenyl)methyl]-2-propan-2-ylmorpholin-4-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine	1699192: Inhibition of full-length C-terminal his-tagged human recombinant CHIT1 catalytic domain (1 to 386 residues) expressed in HEK293F cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N"-triacetylchitotrioside as substrate after 60 mins by fluorometric assay	ic50	0.0180	uM
1-(5-amino-1H-1,2,4-triazol-3-yl)-N-[2-(4-chlorophenyl)ethyl]-N-(oxan-2-ylmethyl)piperidin-4-amine	1516421: Inhibition of full-length C-terminal his-tagged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N\"-triacetylchitotrioside as substrate after 60 mins by fluorometric assay	ic50	0.0210	uM
3-[4-[(2R,5S)-5-[(4-chlorophenyl)methyl]-2-(methoxymethyl)morpholin-4-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine	1699192: Inhibition of full-length C-terminal his-tagged human recombinant CHIT1 catalytic domain (1 to 386 residues) expressed in HEK293F cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N"-triacetylchitotrioside as substrate after 60 mins by fluorometric assay	ic50	0.0220	uM
[(2R,5S)-4-[1-(5-amino-1H-1,2,4-triazol-3-yl)piperidin-4-yl]-5-[(4-chlorophenyl)methyl]morpholin-2-yl]methanol	1699192: Inhibition of full-length C-terminal his-tagged human recombinant CHIT1 catalytic domain (1 to 386 residues) expressed in HEK293F cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N"-triacetylchitotrioside as substrate after 60 mins by fluorometric assay	ic50	0.0220	uM
2-[(2R,5S)-4-[1-(5-amino-1H-1,2,4-triazol-3-yl)piperidin-4-yl]-5-[(4-chlorophenyl)methyl]morpholin-2-yl]propan-2-ol	1699192: Inhibition of full-length C-terminal his-tagged human recombinant CHIT1 catalytic domain (1 to 386 residues) expressed in HEK293F cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N"-triacetylchitotrioside as substrate after 60 mins by fluorometric assay	ic50	0.0230	uM
1-(5-amino-1H-1,2,4-triazol-3-yl)-N-[2-(4-chlorophenyl)ethyl]-N-(oxolan-2-ylmethyl)piperidin-4-amine	1516421: Inhibition of full-length C-terminal his-tagged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N\"-triacetylchitotrioside as substrate after 60 mins by fluorometric assay	ic50	0.0270	uM
(2R,5S)-4-[1-(5-amino-1H-1,2,4-triazol-3-yl)piperidin-4-yl]-5-[(4-chlorophenyl)methyl]-N-methylmorpholine-2-carboxamide	1699192: Inhibition of full-length C-terminal his-tagged human recombinant CHIT1 catalytic domain (1 to 386 residues) expressed in HEK293F cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N"-triacetylchitotrioside as substrate after 60 mins by fluorometric assay	ic50	0.0320	uM
1-(5-amino-1H-1,2,4-triazol-3-yl)-N-[2-(4-chlorophenyl)ethyl]-N-(naphthalen-1-ylmethyl)piperidin-4-amine	1468015: Inhibition of human recombinant full length C-terminal His-tagged chitotriosidase expressed in CHO-K1 cells using 4-methylumbelliferyl-beta-D-N,N’,N\"\"-triacetylchitotrioside as substrate after 60 mins by fluorescence assay	ic50	0.0360	uM
3-[4-[(2R)-2-[(4-chlorophenyl)methyl]piperidin-1-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine	1516421: Inhibition of full-length C-terminal his-tagged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N\"-triacetylchitotrioside as substrate after 60 mins by fluorometric assay	ic50	0.0410	uM
3-[4-[(2S,4R)-2-[(4-chlorophenyl)methyl]-4-methoxypyrrolidin-1-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine	1516421: Inhibition of full-length C-terminal his-tagged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N\"-triacetylchitotrioside as substrate after 60 mins by fluorometric assay	ic50	0.0440	uM
1-(5-amino-1H-1,2,4-triazol-3-yl)-N-[2-(4-chlorophenyl)ethyl]-N-[(2S)-2-methoxypropyl]piperidin-4-amine	1516421: Inhibition of full-length C-terminal his-tagged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N\"-triacetylchitotrioside as substrate after 60 mins by fluorometric assay	ic50	0.0440	uM
3-[4-[(2S,4S)-2-[(4-chlorophenyl)methyl]-4-methoxypyrrolidin-1-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine	1516421: Inhibition of full-length C-terminal his-tagged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N\"-triacetylchitotrioside as substrate after 60 mins by fluorometric assay	ic50	0.0470	uM
3-[4-[(3S)-3-[(4-chlorophenyl)methyl]morpholin-4-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine	1516421: Inhibition of full-length C-terminal his-tagged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N\"-triacetylchitotrioside as substrate after 60 mins by fluorometric assay	ic50	0.0480	uM
2-[[[1-(5-amino-1H-1,2,4-triazol-3-yl)piperidin-4-yl]-[2-(4-chlorophenyl)ethyl]amino]methyl]phenol	1658489: Inhibition of full length recombinant C-terminal His-taged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N’’-diacetylchitotrioside as substrate incubated for 60 mins under shaking condition by microplate fluorometry analysis	ic50	0.0490	uM
(2S,5S)-5-[(4-chlorophenyl)methyl]-2-methyl-4-[1-(1,3-thiazol-2-yl)piperidin-4-yl]morpholine	2090840: Inhibition of human C-terminal His tagged CHIT1 expressed in CHO-K1 cells using 4-methylumbelliferyl beta-D-N,N’,N’’-triacetylchitotrioside as substrate incubated for 60 mins by fluorometric assay	ic50	0.0490	uM
7-benzyl-6-imino-2-oxo-N-(1-phenylethyl)-1,7,9-triazatricyclo[8.4.0.03,8]tetradeca-3(8),4,9,11,13-pentaene-5-carboxamide	1559996: Inhibition of human CHIT1 catalytic domain overexpressed in Pichia pastoris using 4MU-(GlcNAc)2 as substrate after 30 mins by fluorescence based microplate reader analysis	ki	0.0490	uM
3-[4-[(2R)-2-[(4-chlorophenyl)methyl]pyrrolidin-1-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine	1516421: Inhibition of full-length C-terminal his-tagged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N\"-triacetylchitotrioside as substrate after 60 mins by fluorometric assay	ic50	0.0590	uM
3-[[[1-(5-amino-1H-1,2,4-triazol-3-yl)piperidin-4-yl]-[2-(4-chlorophenyl)ethyl]amino]methyl]phenol	1658489: Inhibition of full length recombinant C-terminal His-taged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N’’-diacetylchitotrioside as substrate incubated for 60 mins under shaking condition by microplate fluorometry analysis	ic50	0.0790	uM
(3S,5S)-1-[1-(5-amino-1H-1,2,4-triazol-3-yl)piperidin-4-yl]-5-[(4-chlorophenyl)methyl]pyrrolidin-3-ol	1516421: Inhibition of full-length C-terminal his-tagged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N\"-triacetylchitotrioside as substrate after 60 mins by fluorometric assay	ic50	0.0820	uM
1-(5-amino-1H-1,2,4-triazol-3-yl)-N-[2-(4-chlorophenyl)ethyl]-N-(2-methoxyethyl)piperidin-4-amine	1516421: Inhibition of full-length C-terminal his-tagged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N\"-triacetylchitotrioside as substrate after 60 mins by fluorometric assay	ic50	0.0840	uM
(3R,5S)-1-[1-(5-amino-1H-1,2,4-triazol-3-yl)piperidin-4-yl]-5-[(4-chlorophenyl)methyl]pyrrolidin-3-ol	1516421: Inhibition of full-length C-terminal his-tagged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N\"-triacetylchitotrioside as substrate after 60 mins by fluorometric assay	ic50	0.0870	uM
1-(5-amino-1H-1,2,4-triazol-3-yl)-N-[2-(4-chlorophenyl)ethyl]-N-[(4-chlorophenyl)methyl]piperidin-4-amine	1658489: Inhibition of full length recombinant C-terminal His-taged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N’’-diacetylchitotrioside as substrate incubated for 60 mins under shaking condition by microplate fluorometry analysis	ic50	0.0900	uM
1-(5-amino-1H-1,2,4-triazol-3-yl)-N-[2-(4-chlorophenyl)ethyl]-N-[(2-chlorophenyl)methyl]piperidin-4-amine	1658489: Inhibition of full length recombinant C-terminal His-taged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N’’-diacetylchitotrioside as substrate incubated for 60 mins under shaking condition by microplate fluorometry analysis	ic50	0.1040	uM
1-(5-amino-1H-1,2,4-triazol-3-yl)-N-[2-(4-bromophenyl)ethyl]-N-ethylpiperidin-4-amine	1468015: Inhibition of human recombinant full length C-terminal His-tagged chitotriosidase expressed in CHO-K1 cells using 4-methylumbelliferyl-beta-D-N,N’,N\"\"-triacetylchitotrioside as substrate after 60 mins by fluorescence assay	ic50	0.1050	uM
1-(5-amino-1H-1,2,4-triazol-3-yl)-N-benzyl-N-[2-(4-chlorophenyl)ethyl]piperidin-4-amine	1658489: Inhibition of full length recombinant C-terminal His-taged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N’’-diacetylchitotrioside as substrate incubated for 60 mins under shaking condition by microplate fluorometry analysis	ic50	0.1220	uM
1-(5-amino-1H-1,2,4-triazol-3-yl)-N-[2-(4-bromophenyl)ethyl]-N-(2-methylpropyl)piperidin-4-amine	1468015: Inhibition of human recombinant full length C-terminal His-tagged chitotriosidase expressed in CHO-K1 cells using 4-methylumbelliferyl-beta-D-N,N’,N\"\"-triacetylchitotrioside as substrate after 60 mins by fluorescence assay	ic50	0.1230	uM
1-(5-amino-1H-1,2,4-triazol-3-yl)-N-[2-(4-chlorophenyl)ethyl]-N-(cyclohexylmethyl)piperidin-4-amine	1468015: Inhibition of human recombinant full length C-terminal His-tagged chitotriosidase expressed in CHO-K1 cells using 4-methylumbelliferyl-beta-D-N,N’,N\"\"-triacetylchitotrioside as substrate after 60 mins by fluorescence assay	ic50	0.1230	uM
2-[[amino-(methylcarbamoylamino)methylidene]amino]-N-(4-nitrophenyl)acetamide;2,2,2-trifluoroacetic acid	1940649: Inhibition of human Chitotriosidase using MU-(GlcNAc)2 as substrate incubated for 30 mins by microplate reader analysis	ic50	0.1300	uM
(2S)-1-[[1-(5-amino-1H-1,2,4-triazol-3-yl)piperidin-4-yl]-[2-(4-chlorophenyl)ethyl]amino]propan-2-ol	1516421: Inhibition of full-length C-terminal his-tagged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N\"-triacetylchitotrioside as substrate after 60 mins by fluorometric assay	ic50	0.1450	uM
1-(5-amino-1H-1,2,4-triazol-3-yl)-N-[2-(4-bromophenyl)ethyl]-N-methylpiperidin-4-amine	1468015: Inhibition of human recombinant full length C-terminal His-tagged chitotriosidase expressed in CHO-K1 cells using 4-methylumbelliferyl-beta-D-N,N’,N\"\"-triacetylchitotrioside as substrate after 60 mins by fluorescence assay	ic50	0.1750	uM
1-(5-amino-1H-1,2,4-triazol-3-yl)-N-[2-(4-chlorophenyl)ethyl]-N-[(3-chlorophenyl)methyl]piperidin-4-amine	1658489: Inhibition of full length recombinant C-terminal His-taged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N’’-diacetylchitotrioside as substrate incubated for 60 mins under shaking condition by microplate fluorometry analysis	ic50	0.1760	uM
1-(5-amino-1H-1,2,4-triazol-3-yl)-N-[2-(4-chlorophenyl)ethyl]-N-(oxetan-3-yl)piperidin-4-amine	1516421: Inhibition of full-length C-terminal his-tagged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N\"-triacetylchitotrioside as substrate after 60 mins by fluorometric assay	ic50	0.1800	uM
2-[[amino-(methylcarbamoylamino)methylidene]amino]-N-(3-nitrophenyl)acetamide;2,2,2-trifluoroacetic acid	1940649: Inhibition of human Chitotriosidase using MU-(GlcNAc)2 as substrate incubated for 30 mins by microplate reader analysis	ic50	0.1900	uM
1-(5-amino-1H-1,2,4-triazol-3-yl)-N-[(2-chloro-4-fluorophenyl)methyl]-N-[2-(4-chlorophenyl)ethyl]piperidin-4-amine	1658489: Inhibition of full length recombinant C-terminal His-taged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N’’-diacetylchitotrioside as substrate incubated for 60 mins under shaking condition by microplate fluorometry analysis	ic50	0.2000	uM
1-(5-amino-1H-1,2,4-triazol-3-yl)-N-[2-(4-chlorophenyl)ethyl]-N-(2-methylpropyl)piperidin-4-amine	1658489: Inhibition of full length recombinant C-terminal His-taged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N’’-diacetylchitotrioside as substrate incubated for 60 mins under shaking condition by microplate fluorometry analysis	ic50	0.2290	uM
3-[4-[(3S)-3-[(4-chlorophenyl)methyl]-1-methyl-3,5-dihydro-2H-1,4-benzodiazepin-4-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine	1658489: Inhibition of full length recombinant C-terminal His-taged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N’’-diacetylchitotrioside as substrate incubated for 60 mins under shaking condition by microplate fluorometry analysis	ic50	0.2750	uM
1-(5-amino-1H-1,2,4-triazol-3-yl)-N-[2-(4-chlorophenyl)ethyl]-N-[(2,5-difluorophenyl)methyl]piperidin-4-amine	1658489: Inhibition of full length recombinant C-terminal His-taged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N’’-diacetylchitotrioside as substrate incubated for 60 mins under shaking condition by microplate fluorometry analysis	ic50	0.2770	uM
1-(5-amino-1H-1,2,4-triazol-3-yl)-N-[2-(4-chlorophenyl)ethyl]-N-[[3-(trifluoromethyl)phenyl]methyl]piperidin-4-amine	1658489: Inhibition of full length recombinant C-terminal His-taged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N’’-diacetylchitotrioside as substrate incubated for 60 mins under shaking condition by microplate fluorometry analysis	ic50	0.3100	uM
(2R)-1-[[1-(5-amino-1H-1,2,4-triazol-3-yl)piperidin-4-yl]-[2-(4-chlorophenyl)ethyl]amino]propan-2-ol	1516421: Inhibition of full-length C-terminal his-tagged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N\"-triacetylchitotrioside as substrate after 60 mins by fluorometric assay	ic50	0.3300	uM
(2S,5S)-5-[(4-chlorophenyl)methyl]-2-methyl-4-(1-pyrimidin-5-ylpiperidin-4-yl)morpholine	2090840: Inhibition of human C-terminal His tagged CHIT1 expressed in CHO-K1 cells using 4-methylumbelliferyl beta-D-N,N’,N’’-triacetylchitotrioside as substrate incubated for 60 mins by fluorometric assay	ic50	0.3400	uM
3-[4-[(3S)-3-[(4-chlorophenyl)methyl]-6-methylidene-1,4-oxazepan-4-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine	1658489: Inhibition of full length recombinant C-terminal His-taged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N’’-diacetylchitotrioside as substrate incubated for 60 mins under shaking condition by microplate fluorometry analysis	ic50	0.3500	uM
(17-methoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-16-yl) 6-fluoropyridine-3-carboxylate chloride	1846578: Binding affinity to human Cht expressed in Pichia pastoris GS115 using MU-(GlcNAc)2 as substrate assessed as inhibition constant incubated for 25 mins by dixon plot analysis	ki	0.3500	uM
2-[(2R,5S)-5-[(4-chlorophenyl)methyl]-4-(1-pyridin-2-ylpiperidin-4-yl)morpholin-2-yl]propan-2-ol	2090840: Inhibition of human C-terminal His tagged CHIT1 expressed in CHO-K1 cells using 4-methylumbelliferyl beta-D-N,N’,N’’-triacetylchitotrioside as substrate incubated for 60 mins by fluorometric assay	ic50	0.3780	uM
2-[[1-(5-amino-1H-1,2,4-triazol-3-yl)piperidin-4-yl]-[2-(4-chlorophenyl)ethyl]amino]ethanol	1516421: Inhibition of full-length C-terminal his-tagged human CHIT1 expressed in CHOK1 cells assessed as reduction in chitinolytic activity using 4-methylumbelliferyl-beta-D-N,N’,N\"-triacetylchitotrioside as substrate after 60 mins by fluorometric assay	ic50	0.3840	uM
1-(5-amino-1H-1,2,4-triazol-3-yl)-N-[2-(4-chlorophenyl)ethyl]-N-ethylpiperidin-4-amine	1468015: Inhibition of human recombinant full length C-terminal His-tagged chitotriosidase expressed in CHO-K1 cells using 4-methylumbelliferyl-beta-D-N,N’,N\"\"-triacetylchitotrioside as substrate after 60 mins by fluorescence assay	ic50	0.3850	uM

CTD chemical–gene interactions

19 total (human), top 19 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, affects cotreatment	3
triphenyl phosphate	affects expression	1
propionaldehyde	decreases expression	1
pirinixic acid	increases activity, affects binding, decreases expression	1
bisphenol A	affects cotreatment, increases methylation	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	decreases expression	1
Pioglitazone	decreases expression	1
Arsenic Trioxide	decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Acetaminophen	decreases expression	1
Atrazine	increases expression	1
Azacitidine	increases expression	1
Benzo(a)pyrene	affects methylation	1
Ozone	increases expression	1
Thiram	increases expression	1

ChEMBL screening assays

29 unique, capped per target: 28 binding, 1 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4022941	Binding	Inhibition of human recombinant full length C-terminal His-tagged chitotriosidase expressed in CHO-K1 cells using 4-methylumbelliferyl-beta-D-N,N’,N""-triacetylchitotrioside as substrate after 60 mins by fluorescence assay	Targeting Acidic Mammalian chitinase Is Effective in Animal Model of Asthma. — J Med Chem
CHEMBL4722990	ADMET	Inhibition of human chitinase1 incubated for 70 mins using 4MU-NAG2 as substrate by fluorescence method	Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.